After Several FDA Setbacks, Idenix To Begin Clinical Study Of New HCV Nuc Outside The U.S.
This article was originally published in Pharmaceutical Approvals Monthly
Idenix plans to bypass FDA’s IND process and initiate Phase I/II testing of IDX21437 in Canada and Belgium. It hopes those data will lead to combination testing of the nucleoside polymerase inhibitor with IDX719, its NS5A inhibitor, by 2014.
You may also be interested in...
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.
IBA’s name change refines its identity as the representative of the independent and entrepreneurial beauty industry, according to the trade organization’s announcement. The group’s FDA Cosmetics Regulation Workshop, held annually since 1983 in cooperation with the FDA, will be virtual in 2020.